Baluka D, Urbanek T, Lekstan A, Swietochowska E, Wiaderkiewicz R, Kajor M, Jedrzejewska-Szypulka H, Kusnierz K, Lampe P
Department of Gastrointestinal Surgery, Medical University of Silesia, Katowice, Poland.
Department of General and Vascular Surgery, Medical University of Silesia, Katowice, Poland.
J Physiol Pharmacol. 2016 Feb;67(1):93-101.
Unsatisfactory pancreatic cancer treatment outcomes have prompted multiple avenues of research focused on identifying not only biomarkers of pancreatic adenocarcinoma progression but also potential prognostic survival factors in patients with pancreatic adenocarcinoma. Study consisted of 75 patients who underwent pancreatic resections between 2006 and 2011: 35 patients with pancreatic ductal adenocarcinoma (PC), 30 patients with chronic pancreatitis (CP), and a non-malignant control group (NMCG) of 10 patients who underwent surgery due to benign tumors. Tissue plasminogen activator (t-PA) concentrations in tissue homogenates and sera were evaluated. The mean t-PA concentration in PC tissue homogenates was 12.3 ± 2 (7.5, 15) ng/mg. Compared with the t-PA concentration in the PC group, lower concentrations of t-PA (3.3 ± 0.7 (2.2, 4.7) ng/mg and 5.9 ± 0.8 (4.6, 7.3) ng/mg (P < 0.01)) were observed in tissue homogenates of the CP and the NMCG patients, respectively. Although serum concentrations of t-PA did not differ between patient groups, in PC patients, the t-PA concentrations were higher in sera than in tissue homogenates. In contrast, the CP and NMCG patient groups had lower t-PA concentrations in sera compared with tissue homogenates. Increasing tissue homogenate t-PA concentrations were associated with blood vessels infiltration. Tissue homogenate and serum t-PA concentrations were not related to the survival rate of patients with PC. The t-PA concentration above 7.45 ng/ml in tissue homogenates was indicative of PC. We concluded that higher concentrations of t-PA were observed in pancreatic cancer tissue compared to chronic pancreatitis, suggesting its potential role in the development and progression of pancreatic cancer. In contrast, the lack of significant differences in the serum t-PA concentrations between treatment groups suggests that serum t-PA concentrations may not be suitable as a biomarker for the diagnosis of pancreatic cancer.
胰腺癌治疗效果不尽人意，促使人们开展了多条研究途径，不仅致力于寻找胰腺腺癌进展的生物标志物，还探寻胰腺腺癌患者潜在的预后生存因素。该研究纳入了2006年至2011年间接受胰腺切除术的75例患者：35例胰腺导管腺癌（PC）患者、30例慢性胰腺炎（CP）患者，以及10例因良性肿瘤接受手术的非恶性对照组（NMCG）患者。对组织匀浆和血清中的组织型纤溶酶原激活剂（t-PA）浓度进行了评估。PC组织匀浆中t-PA的平均浓度为12.3±2（7.5，15）ng/mg。与PC组的t-PA浓度相比，CP组和NMCG组患者的组织匀浆中t-PA浓度较低，分别为3.3±0.7（2.2，4.7）ng/mg和5.9±0.8（4.6，7.3）ng/mg（P<0.01）。尽管各患者组间血清t-PA浓度无差异，但在PC患者中，血清t-PA浓度高于组织匀浆中的浓度。相比之下，CP组和NMCG组患者血清中的t-PA浓度低于组织匀浆中的浓度。组织匀浆中t-PA浓度升高与血管浸润相关。组织匀浆和血清t-PA浓度与PC患者的生存率无关。组织匀浆中t-PA浓度高于7.45 ng/ml提示为PC。我们得出结论，与慢性胰腺炎相比，胰腺癌组织中观察到更高浓度的t-PA，表明其在胰腺癌发生和进展中可能发挥作用。相比之下，各治疗组间血清t-PA浓度缺乏显著差异，表明血清t-PA浓度可能不适宜作为胰腺癌诊断的生物标志物。
